Dr Rangan Chatterjee

Doctors Won't Tell You This! - Dark Truth About Antidepressants & How Big Pharma Fooled Everyone

CAUTION: If you are taking antidepressants or any other psychiatric medication, do not stop or adjust your dosage without first consulting a qualified healthcare professional. Coming off these medications without proper guidance can lead to serious withdrawal symptoms. Always seek professional advice before making changes to your treatment. This episode is brought to you by: BON CHARGE: Save 20% off with code LIVEMORE https://boncharge.com/livemore WHOOP: Try the New WHOOP today at https://join.whoop.com/livemore AG1: Get 1 year's Free Vitamin D3+K2 and 5 free travel packs https://bit.ly/43FwxQl VIVOBAREFOOT: Get 20% off your first order https://bit.ly/4l2txWU Did you know that nearly one in five UK adults - and almost one in four women - are currently taking antidepressants? Yet according to my guest this week, the fundamental theory behind these prescriptions may be built on remarkably shaky ground. Joanna Moncrieff is Professor of Critical and Social Psychiatry at University College London, consultant psychiatrist for the NHS, and the author of the groundbreaking book, Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth. In our thought-provoking conversation, Joanna explains how the widely accepted belief that depression is caused by a chemical imbalance or serotonin deficiency has little scientific evidence to support it. This theory, which became popularised in the 1990s through pharmaceutical industry marketing, has fundamentally changed how we view our emotions and mental health. Joanna and I discuss: • Why the difference between antidepressants and placebos in clinical trials is just two points on a 54-point depression scale - a remarkably small difference that may not be clinically significant • How the diagnosis of depression itself is subjective and based on criteria that Joanna describes as "completely made up", rather than objective biological markers • The concerning side effects of SSRIs that are often underreported - including emotional numbness, sexual dysfunction that can persist even after stopping medication, and in some cases, an increase in suicidal thoughts • How pharmaceutical marketing campaigns in the 1990s fundamentally changed our cultural understanding of depression from a natural human response to life circumstances to a "chemical imbalance" requiring medication • Why withdrawal from antidepressants can be extremely challenging, particularly at lower doses, and why reducing medication requires careful, gradual reduction that many doctors aren't trained to manage • Whether visiting your GP should be your first option when experiencing low mood, and how alternatives like exercise, mindfulness and addressing underlying life issues might be more effective Throughout the episode, Joanna encourages us to view our emotional responses as meaningful signals rather than medical disorders that need chemical correction. She believes we've been disempowering people by teaching them that negative emotions represent a deficiency rather than a natural human experience that can guide us toward necessary changes in our lives. This conversation isn't about telling anyone what to do with their current medication, but rather providing information to make truly informed decisions. If you or someone you know has ever taken antidepressants or been diagnosed with depression, this episode offers a perspective that could fundamentally change how you view mental health treatment in the future. I hope you enjoy listening. #feelbetterlivemore ----- Show notes https://drchatterjee.com/563 Connect with Professor Moncrieff: https://x.com/joannamoncrieff https://www.joannamoncrieff.com Professor Moncrieff’s latest book: Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth US https://amzn.to/4kZow1d UK https://amzn.to/43CKC3R #feelbetterlivemore #feelbetterlivemorepodcast ------- Order MAKE CHANGE THAT LASTS. US & Canada version https://amzn.to/3RyO3SL, UK version https://amzn.to/3Kt5rUK ----- Follow Dr Chatterjee at: Website: https://drchatterjee.com/ Facebook: https://www.facebook.com/drchatterjee Twitter: https://twitter.com/drchatterjeeuk Instagram: https://www.instagram.com/drchatterjee/ Newsletter: https://drchatterjee.com/subscription DISCLAIMER: The content in the podcast and on this webpage is not intended to constitute or be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have heard on the podcast or on my website.

RCDr. Rangan ChatterjeehostJMJoanna Moncrieffguest

Jun 11, 2025·1h 49m·Watch on YouTube ↗

📖 CHAPTERS

1. 1

   Why the “chemical imbalance/low serotonin” story became accepted as fact

   Rangan asks why the serotonin-deficiency explanation persists despite weak evidence. Joanna Moncrieff traces how a speculative idea from the 1960s became widely believed after aggressive pharma messaging in the 1990s.

2. 2

   Why mechanism matters: side effects, autonomy, and the ethics of prescribing

   They challenge the claim that “it doesn’t matter how antidepressants work if they help.” Moncrieff argues that mechanism shapes informed consent, risk–benefit decisions, and whether patients feel empowered or dependent on medication.

3. 3

   Common SSRI effects patients report: emotional blunting and feeling unlike oneself

   Moncrieff describes emotional numbing as a frequent SSRI effect—less sadness but also less joy, reduced ability to cry, and a sense of disconnection. Rangan shares clinical experiences of patients reporting “feeling nothing,” questioning whether that constitutes real recovery.

4. 4

   How common are antidepressants now? UK prevalence and rising youth exposure

   They discuss how widespread antidepressant use has become—approaching one in five UK adults, higher among women. Moncrieff notes increasing prescribing among younger people and how normalized medication has become in many social groups.

5. 5

   What the clinical trials really show: small differences vs placebo and shaky blinding

   Moncrieff explains that SSRI trials typically show only a small average advantage over placebo on rating scales. They explore methodological issues: subjective measurement, questionable clinical significance, and “amplified placebo” effects when participants guess their assignment due to side effects.

6. 6

   Diagnosing depression: subjective criteria, rating scales, and cultural/language bias

   They unpack how depression diagnoses are made via symptom criteria and questionnaires rather than objective tests. Both note how wording, cultural interpretation, and presentation style (tearful vs stoic) can change scores and perceived severity.

7. 7

   Why antidepressants became so widespread: marketing, professional incentives, and the lure of simple solutions

   They argue mass prescribing is driven by a “confluence of interests,” led by pharma promotion and reinforced by medical systems. The appeal of a quick, simple fix for complex life problems, plus time-limited consultations and repeat prescribing, sustains high usage.

8. 8

   Placebo, hope, and the hidden downside of pill-based explanations

   They acknowledge many people feel better after starting SSRIs, but emphasize natural recovery, life changes, and hope can explain improvements. Moncrieff cautions that pill-based narratives can create long-term dependency beliefs and discourage skill-building for sustained wellbeing.

9. 9

   A case study in “creating a market”: introducing depression (and antidepressants) to Japan

   Moncrieff recounts an anthropological account of pharma efforts to expand antidepressant sales in Japan, where depression wasn’t widely medicalized. The story illustrates how cultural framing can be reshaped to increase diagnosis and prescribing.

10. 10

    Big harms people may not be warned about: sexual dysfunction, genital anesthesia, and persistence after stopping

    They focus on sexual side effects as both common and under-discussed, with emerging concerns about persistence after discontinuation. Moncrieff highlights reports of genital numbness and long-lasting dysfunction, emphasizing the profound impact on identity and relationships.

11. 11

    What SSRIs do biologically—and what remains uncertain long-term

    Moncrieff explains SSRIs’ primary action (blocking serotonin reuptake transporters) while stressing uncertainty about downstream effects and long-term adaptations. They note serotonin’s role is not fully understood, and chronic use may trigger compensatory changes.

12. 12

    Withdrawal and dependence: why stopping can be hard and often misread as relapse

    They compare SSRI withdrawal to other psychoactive substances (caffeine, alcohol) and discuss how symptoms can be mistaken for returning depression. Moncrieff stresses that abrupt cessation increases risk of severe or prolonged withdrawal, reinforcing long-term use cycles.

13. 13

    How to come off safely: tapering principles, hyperbolic dosing, and practical resources

    Moncrieff advises against suddenly stopping antidepressants and explains why smaller reductions are needed at low doses. They point to practical guidance (Royal College of Psychiatrists materials, Maudsley Deprescribing Guidelines) and note that patient peer communities have led much of the know-how.

14. 14

    What clinicians can do instead: NICE alternatives, informed consent, and rethinking medicalization

    They discuss a shift away from reflex SSRI prescribing toward non-drug supports and better consent discussions. Moncrieff recommends guiding patients toward exercise, mindfulness, problem-solving approaches, CBT/talking therapies, and addressing root-life drivers rather than treating a label.